Research programme: caspase inhibitors - New World Laboratories

Drug Profile

Research programme: caspase inhibitors - New World Laboratories

Alternative Names: NWL 149; NWL 154; NWL 53

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New World Laboratories
  • Class Peptides
  • Mechanism of Action Caspase 1 inhibitors; Caspase 4 inhibitors; Caspase 6 inhibitors; Caspase-3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries; Cancer; Huntington's disease; Inflammation; Multiple sclerosis; Myocardial infarction; Parkinson's disease; Spinal cord injuries; Stroke

Most Recent Events

  • 24 Nov 2016 Research programme: caspase inhibitors - New World Laboratories is available for licensing as of 24 Nov 2016. https://nwl.net/en/partnerships/
  • 24 Nov 2016 Preclinical trials in Alzheimer's disease in Canada (unspecified route)
  • 24 Nov 2016 Preclinical trials in Brain injuries in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top